The first Canadian patient has been dosed in a phase 1/2 trial of a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.
The drug, AURN001 (Aurion Biotech), is a combination cell therapy that consists of neltependocel and Y-27632, according to a press release. AURN001 is intended to be administered to the eye as a one-time intracameral injection.
Approximately 100 patients will be included in the ABA-1/CLARA study, which is designed to examine three different doses of neltependocel used in combination with Y-27632, according